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Abstract 
Introduction: People who inject drugs (PWID) are one of the key populations most vulnerable to HIV infection, with 28 times higher prevalence 
compared to the rest of the population. PWID are known to have many physical, psychological and lifestyle challenges that can influence 
access to care. Depression is common among PWID living with HIV. It has major effect on health-related quality of life (HRQoL) and is 
influencing adherence to antiretroviral therapy. This study was conducted to explore how anxiety and depression affect HRQoL among HIV-
positive PWID in Ukraine. It will provide knowledge for the further policy development.  
Methodology: A descriptive cross-sectional study using data from interviewer- administrated questionnaires was performed. The questionnaire 
was based on the Hospital Anxiety and Depression Scale. The questionnaire on HRQoL was based on the SF-36. 
Results: Among the 90 HIV positive PWID 74% (67) and 61% (55) had anxiety and depression scores higher than 7 respectively, indicating 
that most patients had mental health problems. Average scores for general health (40), role limitations due to physical (44) and emotional health 
(34), vitality (41) and mental health (45) had mean scores less than 50 along with total physical (43) and mental health scores (35). Having an 
HIV positive partner or partner with unknown HIV status increases anxiety in HIV positive PWID. 
Conclusion: There are increased depressive and anxiety symptoms and poorer QoL among HIV-positive PWID in Ukraine. Strategies focusing 
on psychosocial support addressing QoL as part of HIV care could improve health outcomes for these comorbid and debilitating conditions.  
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Introduction 
The human immunodeficiency virus (HIV) 
epidemic is one of the major public health issues 
globally. In 2016, an estimated 36.7 million people 
were living with HIV, and around 30% are not aware of 
their HIV positive status [1]. Despite all HIV 
prevention and treatment activities, one million people 
died of acquired immune deficiency syndrome (AIDS) 
related illnesses [2]. Good health is essential for 
advancement on ending AIDS [2]. Ensuring healthy 
lives and promoting well-being for all, including people 
living with HIV or at risk of having it is part of the 
sustainable development goals (SDG) [3]. According to 
the World Health Organization (WHO) definition 
health is “a state of complete physical, mental and 
social well-being and not merely the absence of disease 
or infirmity” [3]. Access to good health and wellbeing 
is a human right, and the SDG agenda states that 
everyone is entitled to the highest standards of health 
and health care [4]. The SDG target 3.8 on universal 
health coverage (UHC) aims to ensure that all people 
obtain preventive, curative and rehabilitative health 
services without financial hardship [4]. 
People who inject drugs (PWID) are one of the key 
populations most vulnerable to HIV infection. Globally, 
data show that HIV prevalence among people who 
inject drugs is 28 times higher than among the rest of 
the population [5]. The number of PWID worldwide is 
estimated to be 11.7 million, and 14% of them are living 
with HIV. PWIDs represent 0,8 up to 1,2% of Ukrainian 
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population, it makes more than 300 000 persons. There 
are approximately 80 000 PWID living with HIV in 
Ukraine. 
 In 2017, the prevalence of HIV among PWID was 
22.6 % in Ukraine, accounting for the second highest 
rate in Eastern Europe [6] Ukraine ,with a population 
approximately 42 million, covers an area of 600000 km² 
making it the second largest country in Europe after the 
Russian Federation. [7].  
There were 321382 HIV infections registered in 
Ukraine by April 2018, including 105166 AIDS cases 
and 46024 AIDS-related deaths. Infection through 
intravenous drugs remains the driving force of the 
epidemic [8,9]. It is estimated that there are 
approximately 80,000 PWID living with HIV in 
Ukraine. [9–11] In 2017 almost 25% of all new HIV 
cases accounted were observed in this group. 
HIV testing and antiretroviral therapy (ART) were 
introduced through the national program in Ukraine in 
2000. Despite harm reduction services widely 
implemented across the country, which includes rapid 
HIV testing, initiation of medical care among PWID is 
delayed. In 2016 nearly 60% of newly diagnosed PWID 
had a CD4 count less than 350 cells per mL. [11]. 
Moreover, PWID experience disparities in linking to 
medical care, initiating ART and achieving viral 
suppression. Only 10% (7472) of 80,000 HIV infected 
PWID received ART in 2017 [11] Loss to follow-up is 
the major challenge in improving HIV treatment for 
PWID. 
 Poltava, Sumy and Lviv are medium size cities 
with approximate populations of 318000, 293000 and 
733000 respectively (according to the national census 
conducted in 2001), located in eastern and western 
regions of Ukraine. [9] From January 2018 until April 
2018, the number of newly diagnosed HIV positive 
cases in these 3 cities were 133, 81 and 143. Estimated 
numbers of PWID in Poltava are 8200, in Sumy was 
12200 and in Lviv was 11000. More than half of PWID 
are included in harm reduction programs. [11] 
Despite the latest developments in treatment and 
prevention techniques, PWID are known to have many 
physical, psychological challenges and lifestyle 
differences that can influence access to health care. 
Depression is one of the most prevalent mental health 
disorders and is known to have major effect on health-
related quality of life (HRQoL). Symptoms are reported 
in approximately 60% of this group of patients 
influencing adherence to antiretroviral therapy (ART), 
with consequent decrease in immune function and 
acceleration of disease progression [12]. 
Available data suggest that PWID have a lower 
HRQoL compared to other populations, which is known 
to be associated with unemployment, mental health 
problems and frequent injecting practices [13].  
To the best of our knowledge, none of the studies 
explored depression and HRQoL among HIV-positive 
PWIDS in Ukraine. In order to fill the gap, we 
conducted the study in three cities of Ukraine to a) 
describe anxiety and depression among HIV positive 
PWID interviewed with the hospital anxiety and 
depression scale (HADS), b) to describe HRQoL, 
interviewed with the short form health survey (SF-36) 
questionnaire, and c) to assess factors associated with 
anxiety, depression and HRQoL. 
 
Methodology 
Study Design 
A descriptive cross-sectional study using data from 
interviewer- administered questionnaires in three cities 
of Ukraine (Lviv, Sumy, Poltava) was performed. 
 
Study population, sample size 
The study included 90 PWID diagnosed with HIV 
aged 18 years and above who were registered at 
healthcare facilities (N = 49) or were not engaged in 
HIV medical care (N = 41). The convenience sampling 
was used. Study participants registered at healthcare 
facilities were enrolled by nurses and medical doctors, 
respondents not engaged in medical care were enrolled 
by non-government organization’s social workers. 
Inclusion criteria: > 18 years of age, HIV+ status, 
former or current injective drug use, exclusion criteria: 
incomplete clinical profile, use of non-injectable drugs, 
pregnancy. 
 
Variables 
The questionnaire on anxiety and depression was 
based on the HADS. The HADS consists of 14 items, 
seven items each for the anxiety subscale and 
depression subscale. On a responsive scale, each item is 
scored with four alternatives ranging between 0 and 3. 
According to the scale; a total of 8 or above is used as a 
cut-off score for both HADS Anxiety and HADS 
Depression [14,15]. 
The questionnaire on HRQoL was based on the SF-
36, which is a short-form health survey with only 36 
questions. It gives an 8-scale outline of functional 
health and well-being gain as well as psychometrically 
allied physical and mental health summary measures. 
SF-36 scale is intended to evaluate eight health 
domains: (1) physical functioning, (2) social 
functioning, (3) physical-related role limitations, (4) 
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bodily pain, (5) general mental health, (6) emotional-
related role limitations, (7) vitality (energy and fatigue), 
and (8) general health perception. All measures can 
have values from 1 to 100 where greater score indicates 
better quality of life related to the respective domain 
[16–18]. 
Other collected variables included social and 
demographic characteristics, such as age, gender, 
education, employment, personal monthly income, 
marital status, living conditions, history of 
incarceration, partner’s HIV status, HIV status 
disclosure status, and receipt of harm reduction 
services. Behavioral variables were smoking status and 
frequency of drug use.  
Clinical characteristics were linkage to HIV care 
(registration at AIDS center and receiving HIV-related 
check-up), receipt of opioid substitution treatment 
(OST), history of tuberculosis (TB), receipt of ART, 
and reaching undetectable viral load (<40 copies per 
mL). 
 
Data collection 
Data was collected in June and July 2017 through 
an interviewer-administered questionnaire. 
A team of individuals reviewed the cohesiveness of 
the questionnaire before conducting the interviews; four 
interviewers who were trained conducted the interviews 
and collected the information in a standardized manner. 
The interviewer wrote the answers in the interview form 
in Ukrainian. This information was later translated into 
English. Data was entered into IBM® SPSS® Statistics 
database (version 22, IBM Corporation, Armonk, US). 
 
Data analysis 
Data on anxiety, depression, and HRQoL was 
calculated according to the instructions of respective 
questionnaires manual. First, HADS and SF36 scores 
were summarized with descriptive statistics. HADS 
scores on anxiety and depression were categorized as 
borderline or abnormal level if the score was ≥8 cut-
point level. Then, differences in proportions of 
individuals with borderline or abnormal levels of 
anxiety and depression were calculated by Fisher exact 
tests with respect to selected covariates. As for HRQoL 
scores, we calculated mean differences and their 95% 
confidence intervals. The level of significance was set 
at P ≤ 0.05. 
 
Ethics 
The study was approved by the institutional Ethics 
Review board of Lviv Regional Public Health Center, 
Ukraine. All participants gave their informed consent. 
 
Results 
The average age of the study participants was 38.9 
(SD = 7.19). The majority of the study participants were 
males (73%) and unemployed (64%). Most of the study 
participants (67%) had vocational (technical) 
education. 
 
Anxiety and depression 
Table 1 summarizes descriptive statistics for 
anxiety and depression measures as well as for domains 
of SF-36. HADS determine the levels of anxiety and 
depression that a person is experiencing. The mental 
composite score (MCS) of SF-36 includes mental 
health, emotional role, social function and vitality. 
Among the HIV positive PWID, average Anxiety 
and Depression scores were the same (9 out of 18 
points, with a standard deviation (SD) of 4). Seventy-
four percent and 61% had anxiety and depression scores 
higher than cutoff level 7 respectively, which indicates 
that the majority of patients had mental health 
problems. 
Table 1. Descriptive statistics for HADS and SF36 scores among HIV positive PWIDS, in three cities of Ukraine, 2017. 
 N Mean SD Median IQR Min Max 
Anxiety score (HADS) 89 9 4 9 4 0 18 
Depression score (HADS) 90 9 4 10 6 1 18 
Total Physical Health Score (SF36) 89 43 11 44 17 18 64 
Total Mental Health Score (SF36) 89 35 9 34 11 10 57 
Physical Functioning Score (SF36) 90 68 29 70 40 0 100 
Role limitations due to physical health (SF36) 90 44 46 25 100 0 100 
Body Pain (SF36) 90 58 26 62 33 0 100 
General Health (SF36) 90 40 19 40 25 5 117 
Vitality (SF36) 90 41 18 40 25 0 85 
Social Functioning (SF36) 90 61 23 63 25 13 100 
Role limitations due to emotional problems (SF36) 90 34 43 0 67 0 100 
Mental Health (SF36) 90 45 17 44 24 4 80 
HADS – Hospital Anxiety and Depression Scale, SF36 – Short Form Health Survey (36 items), PWID – People who inject drugs, HIV – Human immunodeficiency 
virus, SD – standard deviation, IQR – interquartile range, Min – minimum, Max – maximum. 
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Health-related Quality of life 
With regards to the quality of life among HIV 
positive PWID, mean physical health score was 43 
points out of 100 (SD = 11) and mean mental health 
score was 35 out of 100 (SD = 9). Physical health score 
and mental health score were lower than 50 in 67% and 
92% of patients respectively. Several HRQoL domains 
had mean scores less than 50, which are considered 
lower than the general population. These included 
scores for general health (mean = 40, SD = 19), role 
limitations due to physical health (mean = 44, SD = 46) 
and emotional health (mean = 34, SD = 43), vitality 
(mean = 41, SD = 18) and mental health (mean = 45, 
SD = 17). 
 
Factors associated with anxiety, depression and 
HRQoL 
More anxiety symptoms were reported by PWID 
who had an HIV positive partner or a partner with 
unknown HIV status (p = 0.012) (Table 2). None of 
selected variables were significantly associated with 
borderline/abnormal depressive symptoms.  
Table 2. Factors associated with anxiety and depression among PWIDS in three cities of Ukraine, 2017. 
 
Anxiety (HADS)  Depression (HADS)  
Borderline 
/abnormal 
Normal  
Borderline 
/abnormal 
Normal  
n / 
mean 
% / SD 
n / 
mean 
% / SD p 
n / 
mean 
% / SD 
n / 
mean 
% / SD p 
Gender 
Female 20 83% 3 13% 0.167 14 58% 10 42% 0.744 
Male 47 71% 19 29% - 41 62% 25 38% - 
Education 
Secondary 24 80% 6 20% 0.462 22 73% 8 27% 0.093 
Vocational / higher 43 72% 16 27% - 33 55% 27 45% - 
Monthly income 
> 100 euros 14 64% 7 32% 0.295 12 55% 10 46% 0.467 
≤ 100 euros 53 78% 15 22% - 43 63% 25 37% - 
Employment 
Unemployed 44 76% 13 22% 0.577 38 66% 20 35% 0.248 
Employed 23 72% 9 28% - 17 53% 15 47% - 
Marital status 
Formal / informal 
marriage 
21 64% 11 33% 0.114 22 67% 11 33% 0.411 
Single 46 81% 11 19% - 33 58% 24 42% - 
Living 
conditions 
Lack of own apartment 13 81% 3 19% 0.751 10 63% 6 38% 0.900 
Own house / apartment 54 73% 19 26% - 45 61% 29 39% - 
Duration of trip to healthcare facility, 
minutes 
33 38 31 23 0.819 27 26 41 45 0.105 
Partner's HIV 
status 
HIV negative 13 57% 10 44% 0.012 10 44% 13 57% 0.087 
HIV positive 19 70% 7 26% - 20 74% 7 26% - 
Unknown 35 88% 5 13% - 25 63% 15 38% - 
Smoking 
No 6 67% 3 33% 0.684 4 44% 5 56% 0.294 
Yes 61 76% 19 24% - 51 64% 29 36% - 
Frequency of 
drug use 
Daily 47 70% 19 28% 0.086 40 60% 27 40% 0.567 
Less often 19 91% 2 10% - 14 67% 7 33% - 
Receipt of harm 
reduction 
services 
No 11 73% 4 27% 0.312 7 47% 8 53% 0.233 
Yes 56 76% 17 23% - 47 64% 27 37% - 
OST 
No 30 71% 12 29% 0.426 22 52% 20 48% 0.112 
Yes 37 77% 10 21% - 33 69% 15 31% - 
History of 
incarceration 
No 29 83% 6 17% 0.182 21 60% 14 40% 0.863 
Yes 38 69% 16 29% - 34 62% 21 38% - 
HIV status 
disclosure 
No 12 75% 4 25% 1.000 9 56% 7 44% 0.689 
Yes 55 75% 17 23% - 45 62% 28 38% - 
History of TB 
No 45 73% 16 26% 0.589 37 60% 25 40% 0.771 
Yes 22 82% 5 19% - 17 63% 10 37% - 
Linkage to HIV 
medical care 
No 28 68% 12 29% 0.297 24 59% 17 42% 0.647 
Yes 39 80% 10 20% - 31 63% 18 37% - 
Receipt of ART 
No 16 70% 7 30% 0.461 15 65% 8 35% 0.640 
Yes 51 76% 15 22% - 40 60% 27 40% - 
Undetectable 
viral load (≤ 40) 
No 34 67% 16 31% 0.071 30 59% 21 41% 0.611 
Yes 33 85% 6 15% - 25 64% 14 36% - 
HADS – Hospital Anxiety and Depression Scale, PWID – People who inject drugs, HIV – Human immunodeficiency virus, SD – standard deviation. 
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Greater overall physical health score was associated 
with age less than 38.5 years (mean difference = 4.6, 
95%CI: 0.13-9.06), no receipt of Opioid Substitution 
Therapy (mean difference = 5.1, 95%CI: 0.63-9.47). 
Overall mental health score was lower in those having 
a HIV positive partner (mean difference = -3.8, 95%CI: 
-0.03 to -9.56) or having a partner with unknown HIV 
status (mean difference = -1.5, 95% CI: - 0.35 to -10.05) 
(Table 3). 
Discussion 
This is one of the first studies in Ukraine that is 
exploring anxiety, depression, and HRQoL among HIV 
positive PWID. Anxiety and depression are prevalent in 
the study population. Seven out of every ten HIV 
positive PWID, had anxiety and six out of ten had 
depression. Moreover, assessment of HRQoL disclosed 
that 90% people have low total mental health scores. 
Scores of total physical health as well as five out of 
Table 3. Factors associated with quality of life among PWIDS in three cities of Ukraine, 2017. 
 
Total Physical Health Score (SF36) Total Mental Health Score (SF36) 
Mean SD MD 95% CI Mean SD MD 95% CI 
Gender 
Female 42.2 12.0 -1.1 (-6.7, 4.5) 34.1 7.2 -2.0 (-4.8, 2.7) 
Male 43.4 10.4 ref. ref. 35.2 9.2 ref. ref. 
Age 
Below median 
(38.5 years) 
45.3 10.1 4.6 (0.1, 9.1) 33.5 8.7 0.1 (-6.4, 0.8) 
Median or above 40.7 11.1 ref. ref. 36.3 8.6 ref. ref. 
Education 
Secondary 41.6 10.3 -2.3 (-7.0, 2.5) 32.2 8.6 0.1 (-8.0, -0.3) 
Vocational/ Higher 43.8 11.0 ref. ref. 36.3 8.5 ref. ref. 
Monthly income 
> 100 euros 45.7 10.5 3.5 (-1.7, 8.8) 35.9 7.8 -1.2 (-2.6, 5.4) 
≤ 100 euros 42.2 10.8 ref. ref. 34.5 9.0 ref. ref. 
Employment 
Unemployed 41.8 10.9 -3.6 (-8.3, 1.0) 34.1 9.1 1.3 (-5.8, 1.5) 
Employed 45.4 10.3 ref. ref. 36.3 7.8 ref. ref. 
Marital status 
Formal / informal 
marriage 
42.5 10.5 -0.9 (-5.6, 3.8) 36.8 9.3 1.1 (-1.0, 6.9) 
Single 43.4 11.0 ref. ref. 33.8 8.2 ref. ref. 
Living conditions 
Lack of own 
apartment 
38.6 11.2 -5.4 (-11.8, 0.9) 36.1 10.1 1.7 (-4.2, 7.1) 
Own house / 
apartment 
44.0 10.5 ref. ref. 34.6 8.4 ref. ref. 
Duration of trip to 
healthcare facility, 
minutes 
Below median (20 
minutes) 
43.1 11.4 0.1 (-5.0, 5.2) 34.7 6.7 -2.8 (-3.8, 3.2) 
Median or above 43.0 10.6 ref. ref. 35.0 9.5 ref. ref. 
Partner's HIV status 
HIV negative 43.6 11.2 ref. ref. 38.6 10.2 ref. ref. 
HIV positive 42.2 11.7 -1.4 (-5.1, 7.9) 33.8 6.4 -3.8 (0.0, -9.6) 
Unknown 43.3 10.2 -0.2 (-5.2, 5.8) 33.4 8.7 -1.5 (-0.3, -10.0) 
Smoking 
No 47.8 8.1 5.3 (-1.2, 11.7) 40.9 10.3 1.9 (-1.2, 14.8) 
Yes 42.5 11.0 ref. ref. 34.1 8.4 ref. ref. 
Frequency of drug use 
Daily 43.0 11.0 -0.5 (-6.0, 5.0) 34.5 9.2 1.7 (-5.1, 2.9) 
Less often 43.5 10.7 ref. ref. 35.6 7.5 ref. ref. 
Receipt of harm 
reduction services 
No 44.8 11.7 2.1 (-4.7, 8.9) 36.2 11.2 3.0 (-4.7, 8.1) 
Yes 42.7 10.7 ref. ref. 34.5 8.2 ref. ref. 
OST 
No 45.7 10.0 5.1 (0.6, 9.5) 34.4 9.6 1.7 (-4.6, 2.9) 
Yes 40.7 11.0 ref. ref. 35.3 7.9 ref. ref. 
History of 
incarceration 
No 45.3 10.2 3.6 (-0.9, 8.2) 33.2 9.1 0.7 (-6.6, 1.0) 
Yes 41.6 11.0 ref. ref. 36.0 8.3 ref. ref. 
HIV status disclosure 
No 46.4 8.8 4.1 (-1.2, 9.3) 35.9 7.1 -2.0 (-2.9, 5.6) 
Yes 42.3 11.2 ref. ref. 34.6 9.1 ref. ref. 
History of TB 
No 44.4 10.3 4.8 (-0.5, 10.1) 35.2 9.1 1.4 (-2.5, 5.1) 
Yes 39.7 11.7 ref. ref. 33.9 7.7 ref. ref. 
Linkage to HIV 
medical care 
No 44.2 11.1 2.2 (-2.4, 6.7) 34.8 9.7 1.9 (-4.0, 3.5) 
Yes 42.1 10.5 ref. ref. 35.0 7.8 ref. ref. 
Receipt of ART 
No 44.7 11.1 2.3 (-3.1, 7.7) 34.3 9.8 1.5 (-5.4, 3.9) 
Yes 42.5 10.7 ref. ref. 35.1 8.3 ref. ref. 
Undetectable viral 
load (≤ 40) 
No 42.9 10.8 -0.4 (-5.1, 4.2) 35.0 9.4 1.5 (-3.2, 4.0) 
Yes 43.3 10.9 ref. ref. 34.7 7.9 ref. ref. 
SF36 – Short Form Health Survey (36 items), PWID – People who inject drugs, HIV – Human immunodeficiency virus, SD – standard deviation. 
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eight domains on HRQoL were lower than the average 
in general population. 
Studies conducted in countries such as China and 
South Africa revealed that mental health is a critical 
factor in the adherence of ART regimen [19–21]. Many 
PWID come from a background of high-risk behavior, 
stigmatization, legal constraints, and discrimination 
when positive HIV status disclosed [22].Therefore, the 
findings in this study highlight the importance of 
targeted psychosocial work in this key population to 
ensure adequate level of care. 
The study strengths are that we assessed HIV 
positive PWID using a validated questionnaire to assess 
QoL, depressive and anxiety symptoms. The major 
limitation of the study is the small sample size which 
did not allow adjusted analysis of the data. Another 
limitation of the study is that participants were 
individuals only from the three cities/urban areas in 
Ukraine, so results are not generalizable to overall 
population.  
Nonetheless, the study has policy and practice 
implications. With the advent of effective treatment, 
HIV survival is similar to that of the general population. 
Although our study did not quantify the impact of HIV 
infection compared with other factors on anxiety, 
depression and QoL, it does highlight that HIV positive 
PWID have mental health and QoL needs greater than 
the general population. Thus, health services will need 
to focus on mental health and QoL issues present in 
PWID. 
Finally having a HIV positive partner or partner 
with unknown HIV status increases anxiety rates in 
HIV positive PWID. Other factors are yet to be 
explored in larger scale studies. 
 
Conclusion 
In conclusion, we have highlighted that there are 
increased depressive and anxiety symptoms and poorer 
QoL among HIV-positive PWID in three cities of 
Ukraine. Thus, strategies focusing on psychosocial 
support are urgently needed. Ultimately, addressing 
QoL as part of HIV care could improve health outcomes 
for these comorbid and debilitating conditions. Further 
research using reliable methods to identify causes of 
depressive and anxiety symptoms in key populations as 
well as effective approaches to reduce those symptoms 
and to improve QoL and subsequently HIV care is 
necessary. 
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